Our Global Mission
To establish gene therapy as a new standard of care for the leading causes of vision loss.
For Patients and Caregivers
Adverum aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases with the aspiration of developing functional cures for these diseases to restore vision and prevent blindness. Our lead program is in wet age-related macular degeneration (wet AMD), which is growing as the leading cause of blindness globally, driven by aging populations combined with treatment options that do not effectively stave off blindness in real-world use. The current standard of care consists of painful eye injections (anti-VEGF therapies) delivered by a retinal specialist recurring every 4-8 weeks. Patients undergoing this burdensome treatment regime often miss treatments, putting them at increased risk of losing their sight. Adverum’s investigational gene therapy Ixo-vec is being developed to offer an in-office, single-administration intravitreal (IVT) therapy with the potential to extend treatment benefit from weeks to years.
Using our proprietary, next-generation adeno-associated virus (AAV) vector platform, we are developing Ixo-vec as a long-lasting treatment for wet AMD. Ixo-vec is a vectorized therapeutic protein (aflibercept) treatment designed to transform retinal cells into ocular biofactories that continually produce and dispense therapeutic doses of aflibercept, a proven effective anti-VEGF treatment.
We See Beyond
Adverum aspires to transform the standard of care, preserve long-term vision, and create a profound societal impact around the globe, by advancing gene therapies for highly prevalent ocular diseases. Leveraging the research capabilities of our IVT platform, we design durable medicines that can be administered in the physician’s office, eliminate the need for frequent retinal injections, in an effort to greatly improve accessibility to treatment.
News & Publications
News & Press Releases
Interested in learning more and getting an inside view of Adverum? We are eager to hear from you. Please complete our contact form to engage with one of our team members.